Cambrex Industry Insights

  1. The Delicate Dance: When Phase-Appropriate Decisions Carry More Risk 9/23/2026

     Early drug development demands speed, but some decisions carry long-term consequences. Learn which process and analytical choices require teams to look beyond the next milestone.

  2. Outsourcing Stability Storage: A Cost-Effective And Quality-Driven Approach 8/22/2024

    Partnering with a leader in outsourced stability storage is revolutionizing the pharmaceutical and medical device industry by saving costs and resources, and ensuring product quality and compliance.

  3. Nitrosamine Analysis: Solutions For Risk Management And Analytical Testing 8/22/2024

    Testing for nitrosamines is essential in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and drug products to ensure safety and compliance.

  4. Continuous Manufacturing: An Evolving Technology For Drug Manufacturing 8/21/2024

    Explore the exciting developments in continuous manufacturing and learn how leveraging this innovative technology can help improve manufacturing processes and discover new clinical candidates.

  5. Extractables And Leachables: Risk Management And Analytical Solutions 10/11/2023

    Partnering with a CDMO that offers comprehensive and robust E&L studies can help facilitate a smooth product launch by ensuring minimal impact from impurities, all while mitigating risks.

  6. How Life Science Is Reshaping Supply Chains In Response To COVID-19 1/24/2022

    COVID-19 disruptions led companies to rethink global supply and outsourcing strategies. A survey of 117 biopharma leaders gauged how that experience is shaping attitudes toward resilience.

  7. Digital Transformation In Regulatory: Achieving Excellence Virtually 1/24/2022

    As the industry looks forward, key decisionmakers in pharma and biotech companies were surveyed to assess their views on undertaking regulatory processes virtually.

  8. Balancing Cost Efficiencies In The Drug Development Process 1/24/2022

    Cost efficiencies and expertise again go hand in hand, with companies often outsourcing or partnering primarily to gain access to manufacturing know-how.

  9. Assessing End-To-End Drug Development Partnerships 1/24/2022

    As drug development becomes increasingly expensive and complex, pharma companies are relying on CDMOs to maximize efficiencies. Examine the opportunities and challenges of end-to-end arrangements.

  10. Addressing Development And Manufacturing Upheaval 1/24/2022

    Growing complexity and risks in drug development and supply have implications for outsourcing models. See how to structure and manage CDMO partnerships for a future with uncertainty and disruption.